Changes ahead for US list of drugs with safety concerns
This article was originally published in Scrip
Executive Summary
The US FDAwill improve the transparency and context surrounding public disclosure of medicines that are being evaluated for safety issues. The agency "got the message" that improvements to its first quarterly listing of such products were needed, its center for drug evaluation and research's (CDER) director Dr Janet Woodcock told a drug safety conference cosponsored by the Drug Information Association, the FDA and PhRMA.